Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9911390 | 0.88 | ALDH1A1 (0.44) | ALDH1A1LMNASMN1; SMN2GAAAPOBEC3A | |
| SCHEMBL861154 | 0.88 | ALDH1A1 (0.42) | ALDH1A1LMNASMN1; SMN2GAAAPOBEC3A | |
| SCHEMBL861077 | 0.87 | ALDH1A1 (0.43) | ALDH1A1LMNASMN1; SMN2GAAAPOBEC3A | |
| SCHEMBL13064283 | 0.87 | ALDH1A1 (0.43) | ALDH1A1LMNASMN1; SMN2GAAAPOBEC3A | |
| SCHEMBL9612028 | 0.86 | ALDH1A1 (0.41) | ALDH1A1LMNASMN1; SMN2GAAAPOBEC3A | |
| SCHEMBL9911388 | 0.85 | ALDH1A1 (0.41) | ALDH1A1LMNASMN1; SMN2GAAAPOBEC3A | |
| SCHEMBL861071 | 0.84 | ALDH1A1 (0.41) | ALDH1A1LMNASMN1; SMN2GAAAPOBEC3A | |
| SCHEMBL9911392 | 0.83 | ALDH1A1 (0.42) | ALDH1A1LMNASMN1; SMN2GAAAPOBEC3A | |
| SCHEMBL861029 | 0.83 | ALDH1A1 (0.40) | ALDH1A1LMNASMN1; SMN2GAAAPOBEC3A | |
| SCHEMBL861141 | 0.82 | ALDH1A1 (0.42) | ALDH1A1LMNASMN1; SMN2GAAAPOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372807-B2 | Methods of modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-7517998-B2 | Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2009-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | XDH, PON1, OAT | ALDH1A1 167/4885LMNA 794/4885SMN1; SMN2 1281/4885 |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | RTF1, POLR1A, POLR1E | ALDH1A1 411/4885LMNA 2438/4885SMN1; SMN2 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.